Pacific Biosciences trimmed the high end of its 2026 revenue guidance after lower-than-anticipated instrument demand and continued softness in academic funding, particularly in the Americas. The company now expects full-year revenue of $165 million to $175 million, down from prior guidance that extended to $180 million. PacBio said consumables remain the primary growth engine, supported by clinical utilization and expansion of the Revio and Vega installed base, while delayed consumable orders tied to new sequencing chemistry also weighed on results. The update highlights how platform transitions and research-funding constraints continue to shape sequencing spend and investment timing for genomics stakeholders.